BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labib A, Ju T, Yosipovitch G. Managing Atopic Dermatitis with Lebrikizumab - The Evidence to Date. Clin Cosmet Investig Dermatol 2022;15:1065-72. [PMID: 35702658 DOI: 10.2147/CCID.S295672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim H. Targeting cytokines and signaling molecules related to immune pathways in atopic dermatitis: therapeutic implications and challenges. Arch Pharm Res 2022. [DOI: 10.1007/s12272-022-01421-2] [Reference Citation Analysis]
2 Wallace DV. Treatment options for moderate to severe atopic dermatitis. Allergy Asthma Proc 2022;43:474-93. [PMID: 36335413 DOI: 10.2500/aap.2022.43.220076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pappa G, Sgouros D, Theodoropoulos K, Kanelleas A, Bozi E, Gregoriou S, Krasagakis K, Katoulis AC. The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis. JCM 2022;11:5633. [DOI: 10.3390/jcm11195633] [Reference Citation Analysis]
4 Dodson J, Lio PA. Biologics and Small Molecule Inhibitors: an Update in Therapies for Allergic and Immunologic Skin Diseases. Curr Allergy Asthma Rep 2022;22:183-93. [PMID: 36348149 DOI: 10.1007/s11882-022-01047-w] [Reference Citation Analysis]